Tae Min Kim

Documented advance care planning elements and end-of-life care patterns in malignant glioma vs. major solid tumors: a single-center retrospective study

Ye Sul Jeung, Wan Taek Lee, Yejin Kim, Bhumsuk Keam et autres

kr, us, Éthiopie (code pays fourni par la source)

Lorlatinib in Tyrosine Kinase Inhibitor−Naive Advanced ROS1 -Positive Non−Small Cell Lung Cancer

Beung‐Chul Ahn, Yu Jung Kim, Young Ju Lee, Koung Jin Suh et autres

Importance: ROS1 rearrangement is rare but is an attractive therapeutic target in advanced non-small cell lung cancer (NSCLC). Crizotinib, entrectinib, and repotrectinib have been approved by the US Food and Drug Administration for treatment of ROS1-positive NSCLC. Lorlatinib, a brain-penetrant, third-generation tyrosine …

us, kr (code pays fourni par la source)

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Jing‐Zhou Hou, Tae Min Kim, Seok‐Goo Cho, Sameh Gaballa et autres

Abstract Introduction: Surovatamig (formerly AZD0486) is a novel, IgG4 fully human CD19xCD3 bispecific T-cell engager (TCE) being evaluated in an ongoing phase 1 study in patients (pts) with R/R B-cell non-Hodgkin lymphoma (B-NHL) (NCT04594642). Here, we present long-term follow-up data of surovatamig …

us, kr, gb, jp, au, tw (code pays fourni par la source)

Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with leptomeningeal metastases: the KCSG LU 21-01, LAZARUS study

Hyun Ae Jung, Tae Min Kim, Chang Gon Kim, Hee Kyung Ahn et autres

kr, us (code pays fourni par la source)

T-cell engaging antibodies for B-cell lymphomas

Dong Hyun Kim, Tae Min Kim

Éthiopie, kr (code pays fourni par la source)

Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR -mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase 1 study.

David Ross Camidge, Judith Raimbourg, Yun-Gyoo Lee, Antoine Hollebecque et autres

8512 Background: c-Met protein (also known as MET protein) expression is increased in NSCLC and is a negative prognostic indicator. Temab-A is an ADC comprising the c-Met protein–targeting mAb telisotuzumab conjugated to a novel topoisomerase 1 inhibitor payload. A phase 1 study …

us, fr, kr, es, jp, il (code pays fourni par la source)

SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2 -mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease.

Herbert H. Loong, Lin Li, Lin Wu, Tae Min Kim et autres

8504 Background: The potent, reversible HER2 tyrosine kinase inhibitor BAY 2927088 has demonstrated manageable safety and anti-tumor activity in patients with advanced NSCLC with HER2 -activating mutations. Here we report safety and efficacy data from 2 cohorts of the ongoing, open-label, multicenter …

hk, cn, kr, it, tw, jp, fr, nl, us (code pays fourni par la source)

A phase 2 study of the OX40 agonist BGB-A445, in combination with docetaxel or BGB-15025, an HPK1 inhibitor, in patients with NSCLC pretreated by anti-PD-(L)1 antibodies.

Tae Min Kim, Hai‐Yan Liu, Byoung Chul Cho, Young Ju Lee et autres

e14513 Background: OX40, an immune costimulatory receptor mainly expressed on activated T cells, plays a role in T cell survival, proliferation, and proinflammatory cytokine expression. BGB-A445 is a novel mAb agonist against OX40 with high specificity and affinity that showed preclinical antitumor …

kr, cn (code pays fourni par la source)

Safety and efficacy of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in high-grade neuroendocrine neoplasms.

Alissa J. Cooper, Sreenivasa R Chandana, Muhammad Furqan, Kyriakos P. Papadopoulos et autres

105 Background: SEZ6 is a potential neuroendocrine lineage marker that is expressed in small cell lung cancer (SCLC) and high-grade neuroendocrine neoplasms (NENs). NENs have a significant unmet need for novel effective targeted therapies. ABBV-706, a unique antibody-drug conjugate comprising a SEZ6-directed …

us, kr, au, il (code pays fourni par la source)

Safety and efficacy of AZD0486, a CD19xCD3 T-cell engager, in relapsed or refractory diffuse large B-cell lymphoma.

Tae Min Kim, Dok Hyun Yoon, Sameh Gaballa, Seok‐Goo Cho et autres

7046 Background: Treating relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is challenging despite advances. AZD0486, a novel IgG4 fully human CD19xCD3 bispecific T-cell engager, showed promising safety and efficacy in patients (pts) with heavily pretreated follicular lymphoma with an overall response rate …

kr, us, jp, au (code pays fourni par la source)

Long-term follow-up of the phase 2 ELM-2 study: Odronextamab for patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL).

Deepa Jagadeesh, Michał Taszner, Geoffrey Chong, Silvana Novelli et autres

7049 Background: Odronextamab, an investigational off-the-shelf CD20×CD3 bispecific antibody, demonstrated compelling efficacy and a generally manageable safety profile in heavily pretreated pts with R/R FL in the primary analysis of the Phase 2 ELM-2 study (NCT03888105; Kim TM, et al. Ann Oncol …

us, pl, au, es, kr, it, fr, sg, gb, cn (code pays fourni par la source)

Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study

Tae Min Kim, Nehal J. Lakhani, Jacob D. Soumerai, Manali Kamdar et autres

CD47 overexpression has been associated with tumor cell survival. We present the safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of evorpacept, a novel fusion protein comprising a high-affinity CD47-SIRPα immune checkpoint inhibitor to promote tumor cell phagocytosis and inactive Fc domain to …

Éthiopie, kr, pr, us (code pays fourni par la source)